E. C. T. AND DRUG INDUCED PARKINSONISM by Gangadhar, B.N. et al.
Indian J. Psychiat. (1983), 25(3), 212—213 
E. C. T. AND DRUG INDUCED PARKINSONISM 
B.N. GANGADHAR
1, M.D. 
J. ROY CHOUDHARY', M.B.B.S. 
S.M. CHANNABASAVANNA*, M.D. 
SUMMARY 
A cross-sectional evaluation of the presence of drug induced parkinsonian symptoms in hospi-
talized patients was done. Patients who had received two or more EGTs had lower scores of parkinsonism 
when compared to those who were net receiving EGT. Since the patient groups were comparable on 
parameters which would influence the occurrence and development of drug induced paikinsonism, the 
lowered scores in one group could be attributed to the effect of EGT. 
While EGT has been proved to be 
effective in depression (Gangadhar et al, 
1982) as well as schizophrenia (Janaki-
ramaiah et al., 1982) its benefits in other 
disorders are less proven. Yudofsky (1979) 
observed that EGT relieved both depre-
ssive and parkinsonian symptoms when 
given to a patient suffering from both. 
This observation that parkinsonian sym-
ptoms are relieved by EGT were confir-
med on five patients by Balldin et al. 
(1980) who advocated its use in therapy-
resistent parkinsonism. In this context a 
recent observation (Small et al., 1982) 
that patients treated with EGT plus thio-
thixene had fewer drug induced abnormal 
movements than those treated with thio-
thixens alone is interesting. Is it possible 
that ECT treated patients while on neuro-
leptics develop lesser frequency or severity 
of drug induced EPS ? 
METHODS 
At a cross section all first-admission 
in patients who were receiving EGT and 
a neuroleptic (N=17) were assessed on a 
EPS rating scale (Simpson and Angus, 
1970). All these patients had already 
received at least two ECTs and were cur-
rently still on ECT treatments on alter-
nate days. A control group of first admis-
sion patients (N=18), not receiving ECT 
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were chosen by a stratified random sam-
pling, matching the dosage of neurole-
ptics they were receiving. The EPS scores 
were similary measured. Patient sample 
consisted of only functional psychotics 
other than depressives. Data on other 
factors affecting the onset and severity of 
drug induced parkinsonian symptoms, 
were also collected i.e. age, sex, dur-
ation of neuroleptic therapy, and current 
dosage of antiparkinsonian drug. 
RESULTS 
The patients who were receiving 
EGT and the patients who were not recei-
ving EGT were comparable onparameters 
which would normally affect the deve-
lopment and degree of extra-pyramidal 
reactions (Table 1). 
With regard to neuroleptic drugs, 
the proportion of patients receiving diffe-
rent classes of neuroleptics were similar in 
both the groups. No patient was recei-
ving haloperidal. Six patients in the ECT 
group and seven patients in the no ECT 
group were receiving thrifluperazine. The 
remaining patients were on chlorpro-
mazine. Three patients in the ECT 
group and two patients in the no ECT 
group were receiving weekly fluperazine 
deconoate (25 mgm) injections in addi-
tion to chlorpromazine. The neuroleptic 
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TABLE I 
ECT NO ECT 
(n = 17) (n = 18) 
Agt (iayears) 
28.5±8.7 31.9±9.1 NS 
Sex 
Male 7 8 
Female 10 10 NS 
Dosage of Neuroleptics 570^284 528±181 NS 
Chlorpromazine mgm/ 
day. 
Duration of Neuro-
leptic Therapy (days) 25.4±20.2 27.5±22.0 NS 
Dosage of Benzhexol 
mgm/day 1.9±2.1 3.1±2.2 NS 
EPS score. 1.0±1.1 5.5±3.8 t=5.26 
p<0.001 
dosage was converted into chlorproma-
zine equivalents and there was no stati-
stically significant difference between the 
groups. The patients receiving ECT, 
on the average had received 5.2 EGTs 
each. The ESP scores in this group were 
significantly lower (p<0.001). 
DISCUSSION 
It has been established that parkinso-
nian symptoms develop due to a functi-
onal deficiency of dopamine activity (DA) 
and enhanced central cholinergic activity. 
Use of anticholinergic drugs is known to 
alleviate such symptoms. ECT has been 
shown to increase DA receptor sensitivity 
(Balldin et al., 1982) and hence might 
explain beneficial effect in parkinsonian 
symptoms. A theoretical paradox does 
exist as to why it is also beneficial in schi-
zophrenia (Janakiramaiah et al., 1982); 
Small et al.., 1982), a disease believed 
to be due to increased central dopaminer-
gic hyperactivity. Nevertheless, the ob-
servation that patients treated with ECT 
had lower mean EPS scores is encoura-
ging in favour of use of ECT in conjun-
ction with neuroleptics. 
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